Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1107 publications

Cost-effectiveness analysis of sugemalimab plus chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction cancer.

Cost-effectiveness analysis of sugemalimab plus chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction cancer.

Journal: Human vaccines & immunotherapeutics
Published: January 12, 2026

Durable Complete Response and Potential Cure With Systemic Chemotherapy in Metastatic Gastric Cancer: A Case Series of Patients.

Durable Complete Response and Potential Cure With Systemic Chemotherapy in Metastatic Gastric Cancer: A Case Series of Patients.

Journal: JCO oncology practice
Published: December 19, 2025

Redefining gastroesophageal junction cancer care with perioperative immunotherapy, minimal residual disease monitoring and new targets.

Redefining gastroesophageal junction cancer care with perioperative immunotherapy, minimal residual disease monitoring and new targets.

Journal: Nature reviews. Gastroenterology & hepatology
Published: December 18, 2025

Ocular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study.

Ocular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study.

Journal: Ocular immunology and inflammation
Published: December 13, 2025

Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.

Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.

Journal: Annals of medicine
Published: December 10, 2025

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases.

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases.

Journal: Future oncology (London, England)
Published: November 28, 2025

Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study.

Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study.

Journal: Future oncology (London, England)
Published: November 26, 2025

Trastuzumab deruxtecan in the treatment of HER2-positive gastric cancer: a comprehensive review.

Trastuzumab deruxtecan in the treatment of HER2-positive gastric cancer: a comprehensive review.

Journal: Future oncology (London, England)
Published: November 19, 2025

Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience.

Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience.

Journal: Journal of cancer research and clinical oncology
Published: November 16, 2025

Application of esophageal-tubular gastric asymmetric anastomosis in esophageal and esophagogastric junction cancer

Application of esophageal-tubular gastric asymmetric anastomosis in esophageal and esophagogastric junction cancer

Journal: Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Published: October 26, 2025

First-line PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for advanced esophageal and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials.

First-line PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for advanced esophageal and gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials.

Journal: Journal of gastrointestinal oncology
Published: October 16, 2025

Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study.

Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study.

Journal: Annals of medicine
Published: October 11, 2025
Showing 1-12 of 1,107

Last Updated: 02/24/2026